iBio, Inc. Common Stock (IBIO) Stock
NASDAQ · IBIO
1.16
Fundamentals
Market cap
$76.53M
Price / Earnings ratio
-2.3x
Price / Sales ratio
772.0x
Price / Book ratio
0.9x
Return on assets
-47.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
NeutralIBIOFebruary 2, 2026
Zacks Investment ResearchNeutral
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
IBIO

Stocktwits
IBIO Stock Soars 12% Pre-Market After Company Announces $26 Million Private Placement
NeutralIBIOJanuary 9, 2026
StocktwitsNeutral
IBIO Stock Soars 12% Pre-Market After Company Announces $26 Million Private Placement
IBIO

InvestorPlace
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
NeutralIBIOApril 5, 2024
InvestorPlaceNeutral
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
IBIO

InvestorPlace
Ticking Time Bombs: 3 Healthcare Stocks to Dump Before the Damage Is Done
NeutralIBIOSeptember 28, 2023
InvestorPlaceNeutral
Ticking Time Bombs: 3 Healthcare Stocks to Dump Before the Damage Is Done
IBIO
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
2026
4800003168001584000
Debt & Balance Sheet
Total assets
Total liabilities
2025
2026
119M78M39M0
Revenue to Profit
2026$100000.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-33.0M
Net incomeEarnings
No data available
% positive news of 9 articles
published over the past 14 days
Latest news

Zacks Investment Research
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
NeutralIBIOFebruary 2, 2026
Zacks Investment ResearchNeutral
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
IBIO

Stocktwits
IBIO Stock Soars 12% Pre-Market After Company Announces $26 Million Private Placement
NeutralIBIOJanuary 9, 2026
StocktwitsNeutral
IBIO Stock Soars 12% Pre-Market After Company Announces $26 Million Private Placement
IBIO

InvestorPlace
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
NeutralIBIOApril 5, 2024
InvestorPlaceNeutral
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
IBIO

InvestorPlace
Ticking Time Bombs: 3 Healthcare Stocks to Dump Before the Damage Is Done
NeutralIBIOSeptember 28, 2023
InvestorPlaceNeutral
Ticking Time Bombs: 3 Healthcare Stocks to Dump Before the Damage Is Done
IBIO

InvestorPlace
3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever
NeutralIBIOJune 20, 2023
InvestorPlaceNeutral
3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever
IBIO

InvestorPlace
7 Stocks to Sell as Banks Melt Down
NeutralIBIOMarch 20, 2023
InvestorPlaceNeutral
7 Stocks to Sell as Banks Melt Down
IBIO

InvestorPlace
7 Penny Stocks to Sell Before They Plunge in 2023
NeutralIBIODecember 8, 2022
InvestorPlaceNeutral
7 Penny Stocks to Sell Before They Plunge in 2023
IBIO

InvestorPlace
7 Short-Squeeze Stocks to Sell Before Traders Cash Out
NeutralIBIOOctober 19, 2022
InvestorPlaceNeutral
7 Short-Squeeze Stocks to Sell Before Traders Cash Out
IBIO

InvestorPlace
3 Healthcare Stocks to Sell Before They Die
NeutralIBIOSeptember 30, 2022
InvestorPlaceNeutral
3 Healthcare Stocks to Sell Before They Die
IBIO
About iBio, Inc. Common Stock
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
SectorHealthcare
IndustryBiotechnology
Employees23
CEODr. Martin B. Brenner D.V.M., Ph.D.
IPO DateAug 19, 2008
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Martin B. Brenner D.V.M., Ph.D. | CEO, Chief Scientific Officer & Director | 1970 |
Fundamentals
Valuation
Market cap$76.53M
Price-to-sales ratio772.00
Price-to-book value0.90
Price-earnings ratio-2.30
Return on Equity-54.00%
Return on Sales-9154.00%
Return on Assets-47.00%
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-0.32
Income Statement
Average volume618,126
EBITDA$-26.40M
1 year high (52w)$3.82
1 year low (52w)$0.78
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$6.00
Est return
421.74%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +15.1 | -29.4 | -13.3 | +19.5 | -7.4 | -20.0 | -10.6 | -5.6 |



